Pyruvate Kinase M2: A New Biomarker for the Early Detection of Diabetes-Induced Nephropathy

• Published in: International journal of molecular sciences Vol. 24; no. 3; p. 2683
• Main Authors: Park, Yeon Su, Han, Joo Hee, Park, Jae Hyeon, Choi, Ji Soo, Kim, Seung Hyeon, Kim, Hyung Sik
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 31.01.2023; MDPI
• Subjects: Animals; Biomarkers; Clinical trials; Creatinine; Diabetes; Diabetes Mellitus; Diabetic Nephropathies - etiology; Diabetic nephropathy; Early Diagnosis; Enzymes; Food; Kidney diseases; Kinases; Lipocalin-2; Pathogenesis; Proteins; Pyruvate Kinase - metabolism; Rats; Rats, Zucker; Urine; nephropathy; urinary excretion; biomarker; diabetes; pyruvate kinase M2
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms24032683

Diabetic nephropathy (DN) is a common complication of diabetes. DN progresses to end-stage renal disease, which has a high mortality rate. Current research is focused on identifying non-invasive potential biomarkers in the early stage of DN. We previously indicated that pyruvate kinase M2 (PKM2) is excreted in the urine of rats after cisplatin-induced acute kidney injury (AKI). However, it has not been reported whether PKM2 can be used as a biomarker to diagnose DN. Therefore, we try to compare whether the protein PKM2 can be detected in the urine samples from diabetic patients as shown in the results of DN models. In this study, high-fat diet (HFD)-induced Zucker diabetic fatty (ZDF) rats were used for DN phenotyping. After 19 weeks of receiving a HFD, the DN model’s blood glucose, blood urea nitrogen, and serum creatinine levels were significantly increased; severe tubular and glomerular damages were also noted. The following protein-based biomarkers were increased in the urine of these models: kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), and PKM2. PKM2 had the earliest detection rate. In the urine samples of patients, PKM2 protein was highly detected in the urine of diabetic patients but was not excreted in the urine of normal subjects. Therefore, PKM2 was selected as the new biomarker for the early diagnosis of DN. Our results reflect current knowledge on the role of PKM2 in DN.